https://www.prnewswire.com/news-releases/daiichi-sankyos-pexidartinib-demonstrated-further-improvement-with-continued-treatment-of-tenosynovial-giant-cell-tumor-patients-in-new-long-term-analysis-presented-at-2019-asco-annual-meeting-300860162.html
Daiichi Sankyo's Pexidartinib Demonstrated Further Improvement with Continued Treatment of...
/PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that new data from a pooled analysis of the phase 3 ENLIVEN...
daiichi sankyopexidartinibdemonstrated
https://www.prnewswire.com/news-releases/ema-validates-daiichi-sankyos-marketing-authorization-application-for-pexidartinib-for-treatment-of-patients-with-tgct-a-rare-debilitating-non-malignant-tumor-300823819.html
EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment...
/PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the European Medicines Agency (EMA) validated the Marketing...
daiichi sankyomarketing authorizationema